论文部分内容阅读
目的探讨卡介菌多糖核酸注射液(BCG-PNA)治疗婴幼儿哮喘的临床疗效。方法选择2004年3月至2006年9月于我院就诊的60例1～4岁的哮喘婴幼儿,应用随机数目表法将来院就诊的患儿分为治疗组32例(应用BCG-PNA组)和对照组28例。观察治疗前后酶联免疫吸附试验检测血清IgE、白细胞介素-4(IL-4)、γ-干扰素(IFN-γ)、IL-12、结核菌素纯蛋白衍生物(PPD)试验,哮喘的发作程度的变化及疗效的评价。结果与对照组比较,治疗组患儿IL-4、IL-12、IFN-γ、PPD的变化差异有统计学意义(P<0.05),哮喘发作程度、临床疗效差异也存在统计学意义(P<0.01)。结论卡介菌多糖核酸注射液有明显治疗作用,可作为防治婴幼儿哮喘的有效方法之一。
Objective To investigate the clinical efficacy of BCG polysaccharide nucleic acid injection (BCG-PNA) in the treatment of infantile asthma. Methods Sixty infants and young children aged 1-4 years old who were treated in our hospital from March 2004 to September 2006 were divided into treatment group (32 cases) treated with BCG-PNA group ) And control group 28 cases. Serum IgE, IL-4, IFN-γ, IL-12, PPD test and asthma were observed before and after treatment by enzyme-linked immunosorbent assay The degree of seizure changes and evaluation of efficacy. Results Compared with the control group, there were significant differences in the changes of IL-4, IL-12, IFN-γ and PPD between the treatment group and the control group (P <0.05), and there was also a statistically significant difference in the degree of asthma attack and the clinical efficacy <0.01). Conclusion BCG polysaccharide nucleic acid injection has a significant therapeutic effect, can be used as an effective method of prevention and treatment of infant asthma.